Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.

CONCLUSIONS In conclusion, our results showed that Carnosic acid has the potential to inhibit cancer cell growth in A-549 lung cancer cells by activating apoptotic death, inhibiting cell migration and invasion and suppressing PI3K/AKT/m-TOR signaling pathway. PMID: 31631173 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research

Related Links:

Nivolumab is a fully human, immunoglobulin G4 (kappa) isotype monoclonal antibody that binds programmed cell death protein 1 (PD-1) on activated immune cells and disrupts the engagement of the receptor with its ligands programmed death-ligand 1 (PD-L1: B7-H1/CD274 and PD-L2: B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the antitumor response of the host [1]. In previous clinical trials, nivolumab has shown activity in several tumor types, including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), hodgkin lymphoma, and malignant pleural mesothelioma.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Diagnostic Test: Tumor Imaging;   Procedure: Tumor Tissue Collection;   Procedure: Blood Sample Collection Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Biological: MK-5890 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Biological: MK-4830 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Biological: MK-7684 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Biological: MK-5890 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Biological: MK-4830 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Biological: MK-7684 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Biological: MK-5890 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biomedical Science | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Research | Science | Study